Recent developments in the use of chemotherapy in brain tumours

被引:119
作者
van den Bent, MJ
Hegi, ME
Stupp, R
机构
[1] Erasme Univ Hosp, Dr Daniel Den Hoed Canc Ctr, Dept Neurooncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Lausanne Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, Lausanne, Switzerland
[3] Univ Lausanne Hosp, Multidisciplinary Oncol Ctr, Lausanne, Switzerland
关键词
glioblastoma; oligodendroglioma; anaplastic glioma; temozolomide; radiotherapy; PCV; MGMT;
D O I
10.1016/j.ejca.2005.06.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several recent studies have further clarified the role of chemotherapy in newly diagnosed anaplastic glioma. For newly diagnosed glioblastoma, combined daily radiotherapy with daily temozolomide followed by six cycles of adjuvant temozolomide improves overall survival. This benefit is especially observed in patients with a methylated promotor of the MGMT gene which encodes an alkyltransferase; this observation however, needs confirmation. Although oligodendroglial tumours are sensitive to chemotherapy, classical adjuvant nitrosourea-based chemotherapy does not improve overall survival in newly diagnosed anaplastic oligodendroglioma, even in the subset of 1p/19q loss tumours. It may increase progression-free survival however, and further studies must show if combined modality treatment with daily chemotherapy during radiotherapy increases survival. Trials exploring the role of chemotherapy in low-grade glioma are ongoing. No standard chemotherapy is currently available for highly anaplastic glioma failing first-line temozolomide-based therapy. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:582 / 588
页数:7
相关论文
共 63 条
  • [1] Afra D, 2002, LANCET, V359, P1011
  • [2] Belanich M, 1996, CANCER RES, V56, P783
  • [3] Intracellular localization and intercellular heterogeneity of the human DNA repair protein O-6 methylguanine-DNA methyltransferase
    Belanich, M
    Randall, T
    Pastor, MA
    Kibitel, JT
    Alas, LG
    Dolan, ME
    Schold, SC
    Gander, M
    Lejeune, FJ
    Li, BFL
    White, AB
    Wasserman, P
    Citron, ML
    Yarosh, DB
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 37 (06) : 547 - 555
  • [4] Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine
    Biemond-ter Stege, EM
    Kros, JM
    de Bruin, HG
    Enting, RH
    van Heuvel, I
    Looijenga, LHJ
    van der Rijt, CDD
    Smitt, PAES
    van den Bent, MJ
    [J]. CANCER, 2005, 103 (04) : 802 - 809
  • [5] Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies
    Brada, M
    Judson, I
    Beale, P
    Moore, S
    Reidenberg, P
    Statkevich, P
    Dugan, M
    Batra, V
    Cutler, D
    [J]. BRITISH JOURNAL OF CANCER, 1999, 81 (06) : 1022 - 1030
  • [6] Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas
    Brada, M
    Viviers, L
    Abson, C
    Hines, F
    Britton, J
    Ashley, S
    Sardell, S
    Traish, D
    Gonsalves, A
    Wilkins, P
    Westbury, C
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (12) : 1715 - 1721
  • [7] Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
    Brada, M
    Hoang-Xuan, K
    Rampling, R
    Dietrich, PY
    Dirix, LY
    Macdonald, D
    Heimans, JJ
    Zonnenberg, BA
    Bravo-Marques, JM
    Henriksson, R
    Stupp, R
    Yue, N
    Bruner, J
    Dugan, M
    Rao, S
    Zaknoen, S
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (02) : 259 - 266
  • [8] How effective is BCNU in recurrent glioblastoma in the modern era?: A phase II trial
    Brandes, AA
    Tosoni, A
    Amistà, P
    Nicolardi, L
    Grosso, D
    Berti, F
    Ermani, M
    [J]. NEUROLOGY, 2004, 63 (07) : 1281 - 1284
  • [9] First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia
    Brandes, AA
    Basso, U
    Reni, M
    Vastola, F
    Tosoni, A
    Cavallo, G
    Scopece, L
    Ferreri, AJ
    Panucci, MG
    Monfardini, S
    Ermani, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1598 - 1604
  • [10] Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy:: A phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
    Brandes, AA
    Tosoni, A
    Basso, U
    Reni, M
    Valduga, F
    Monfardini, S
    Amistà, P
    Nicolardi, L
    Sotti, G
    Ermani, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) : 4779 - 4786